New drug cocktail shows promise against deadly thyroid cancer before surgery

NCT ID NCT04675710

First seen Oct 31, 2025 · Last updated Apr 23, 2026 · Updated 26 times

Summary

This study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help doctors more completely remove a rare and fast-growing thyroid cancer called anaplastic thyroid cancer. The trial includes 30 adults whose cancer has a specific BRAF gene mutation. The goal is to see if this approach improves survival and allows for full tumor removal.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio, 44195, United States

  • Huntsman Cancer Institute at the University of Utah

    Salt Lake City, Utah, 84112, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic

    Rochester, Minnesota, 55901, United States

  • Stanford School of Medicine

    Stanford, California, 94304, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.